According to a recent LinkedIn post from Supira Medical Inc, the company used the PCR cardiology meeting to engage with physicians and collaborators around its next-generation percutaneous ventricular assist device system. The post suggests that discussions focused on how this technology could reshape the pVAD segment in high-risk percutaneous coronary intervention and cardiogenic shock settings.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post highlights that the Supira System is designed to reduce procedural risks, broaden access to care, and improve ease of use through a custom low-profile 10Fr introducer. It also notes technical specifications such as up to 5.5 liters per minute of continuous flow and dual sensors for real-time aortic and ventricular pressure monitoring, features that may position the device competitively if successfully commercialized.
As emphasized in the post, the Supira System remains an investigational device and is not approved for sale in the U.S. or any market, meaning no near-term revenue contribution should be assumed from this product. However, investor-oriented interpretation of the post points to continued development progress and growing clinical engagement, which could support Supira Medical Inc’s long-term prospects in mechanical circulatory support if regulatory and clinical milestones are achieved.